Curcumin polymers as anticancer conjugates

Biomaterials

Volumn 31, Issue 27, 2010, Pages 7139-7149

  Tang, Huadong ^b   Murphy, Caitlin J ^c   Zhang, Bo ^b   Shen, Youqing ^a,b   Van Kirk, Edward A ^c   Murdoch, William J ^c   Radosz, Maciej ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING   (United States)

^c UNIVERSITY OF WYOMING   (United States)

Author keywords

Curcumin conjugate; Curcumin polymer; Drug delivery; In vivo antitumor activity

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTICANCER ACTIVITIES; CANCER CELL LINES; CANCER CELLS; CASPASE-3; CELL APOPTOSIS; CELL CYCLE; CONDENSATION POLYMERIZATION; CURCUMIN; CYTOTOXIC; DRUG LOADING; DRUG-CONJUGATES; DRUG-LOADING EFFICIENCY; HIGH MOLECULAR WEIGHT; IN-VITRO; IN-VIVO; IN-VIVO TESTS; INTRAPERITONEAL; MCF-7 BREAST CANCER CELLS; OVARIAN CANCERS; POLYACETALS; POLYMER DRUGS; POTENTIAL APPLICATIONS; TUMOR MODELS; WATER SOLUBILITIES;

BIOCHEMISTRY; CELL CULTURE; CELL DEATH; DRUG DELIVERY; POLYCONDENSATION;

POLYMERS;

CASPASE 3; CURCUMIN; POLYCURCUMIN PCURC 8; POLYMER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONJUGATE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LYSOSOME; MOUSE; NONHUMAN; OVARY CANCER; POLYMERIZATION; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; SYNTHESIS; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 3; CURCUMIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; POLYMERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954382855     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.06.007     Document Type: Article

References (53)

1. The molecular targets and therapeutics of curcumin in health and disease 2007, Springer. B.B. Aggarwal, Y.H. Surh, S. Shishodia (Eds.).
2. Strimpakos A.S., Sharma R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008, 10(3):511-546.
3. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic diseases. Int J Biochem Cell Biol 2009, 41(1):40-59.
4. Somparn P., Phisalaphong C., Nakornchai S., Unchern S., Morales N.P. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 2007, 30(1):74-78.
5. Menon V.P., Sudheer A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007, 595:105-125.
6. Chen D., Nie M., Fan M.W., Bian Z. Anti-inflammatory activity of curcumin in macrophages stimulated by lipopolysaccharides from Porphyromonas gingivalis. Pharmacology 2008, 82(4):264-269.
7. Bar-Sela G., Epelbaum R., Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010, 17(3):190-197.
8. Reuter S., Eifes S., Dicato M., Aggarwal B.B., Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 2008, 76(11):1340-1351.
9. Singh S., Aggarwa B.B. Activation of transcription factor NF-kB is suppressed by curcumin (diferulolylmethane). J Biol Chem 1995, 270(42):24995-25000.
10. Kunnumakkara A.B., Anand P., Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269(2):199-225.
11. Farombi E.O., Shrotriy S., Surh Y.-J. Kolaviron inhibits dimethyl nitrosamine-induced liver injury by suppressing COX-2 and iNOS expression via NF-κB and AP-1. Life Sci 2009, 84(5-6):149-155.
12. Liu J.Y., Lin S.J., Lin J.K. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoylphorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 1993, 14(5):857-861.
13. Shukla S., Zaher H., Hartz A., Bauer B., Ware J.A., Ambudkar S.V. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res 2008, 26(2):480-487.
14. Zhang W., Tan T.M.C., Lim L.-Y. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 2006, 35(1):110-115.
15. Sandur S.K., Pandey M.K., Sung B., Ahn K.S., Murakami A., Sethi G., et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007, 28(8):1765-1773.
16. Song G., Mao Y.B., Cai Q.F., Yao L.M., Ouyang G.L., Bao S.D. Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res 2005, 38(12):1791-1798.
17. Li L., Braiteh F.S., Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104(6):1322-1331.
18. Purkayastha S., Berlinerb A., Fernandoa S.S., Ranasinghe B., Ray I., Tariq H., et al. Curcumin blocks brain tumor formation. Brain Res 2009, 1266(17):130-138.
19. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N., et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kB pathway. Clin Cancer Res 2007, 13(11):3423-3430.
20. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21(4B):2895-2900.
21. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10(20):6847-6854.
22. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4(6):807-818.
23. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14(14):4491-4499.
24. Wang Y.-J., Pan M.-H., Cheng A.-L., Lin L.-I., Ho Y.-S., Hsieh C.-Y., et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997, 15(12):1867-1876.
25. Huang M.-T., Newmark H.L., Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem Suppl 1997, 27:26-34.
26. Liang G., Shao L., Wang Y., Zhao C., Chu Y., Xiao J., et al. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem 2009, 17(6):2623-2631.
27. Youssef D., Nichols C.E., Cameron T.S., Balzarini J., De Clercq E., Jha A. Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg Med Chem Lett 2007, 17(20):5624-5629.
28. Li L., Ahmed B., Mehta K., Kurzrock R. Liposomal curcumin with and without oxaliplat, effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007, 6(4):1276-1282.
29. Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009, 125(1):1-8.
30. Chen C., Johnston T.D., Jeon H., Gedaly R., McHugh P.P., Burke T.G., et al. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int J Pharm 2009, 366(1-2):133-139.
31. Shankeshi J., Aukunuru J. Preparation, characterization and evaluation of antidiabetic activity of a liposomal formulation encapsulating curcumin, an ayurvedic natural product. Pharmacist 2008, 3(2):1-5.
32. Marczylo T.H., Verschoyle R.D., Cooke D.N., Morazzoni P., Steward W.P., Gescher A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007, 60(2):171-177.
33. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., et al. Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin" ): a novel strategy for human cancer therapy. J Nanobiotechnol 2007, 5(3):1-18.
34. Das R.K., Kasoju N., Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine 2010, 6(1):153-160.
35. Cartiera M.S., Ferreira E.C., Caputo C., Egan M.E., Caplan M.J., Saltzman W.M. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol Pharm 2010, 7(1):86-93.
36. Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010, 79(3):330-338.
37. Shi W., Dolai S., Rizk S., Hussain A., Tariq H., Averick S., et al. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org Lett 2007, 9(26):5461-5464.
38. Safavy A., Raisch K.P., Mantena S., Sanford L.L., Sham S.W., Krishna N.R., et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem 2007, 50(24):6284-6288.
39. Tomlinson R., Klee M., Garrett S., Heller J., Duncan R., Brocchini S. Pendent chain functionalized polyacetals that display pH-dependent degradation: a platform for the development of novel polymer therapeutics. Macromolecules 2002, 35(2):473-480.
40. Kunwar A., Barik A., Mishra B., Rathinasamy K., Pandey R., Priyadarsini K.I. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta 2008, 1780(4):673-679.
41. Lin S.-S., Huang H.-P., Yang J.-S., Wud J.-Y., Hsai T.-C., Lin C.-C., et al. DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade- and mitochondrial-dependent pathway. Cancer Lett 2008, 272(1):77-90.
42. Choudhuri P.S.T., Das T., Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005, 20:20059-20068.
43. Jacot J.G., Wong J.Y. Endothelial injury induces vascular smooth muscle cell proliferation in highly localized regions of a direct contact co-culture system. Cell Biochem Biophys 2008, 52(1):37-46.
44. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Cyclin D1: normal and abnormal functions. Endocrinology 2004, 145(12):5439-5447.
45. Hengstschlager M., Braun K., Soucek T., Miloloza A., Hengstschlager-Ottnad E. Cyclin-dependent kinases at the G1-S transition of the mammalian cell cycle. Mutat Res 1999, 436(1):1-9.
46. Kopeček J., Kopeckova P., Minko T., Lu Z.R., Peterson C.M. Water soluble polymers in tumor targeted delivery. J Control Release 2001, 74(1-3):147-158.
47. Thistlethwaite A.J., Leeper D.B., Moylan D., Nerlinger R.E. pH distribution in human tumors. Int J Rad Oncol Biol Phys 1985, 11(9):1647-1652.
48. Reijngoud D.J., Tager J.M. The permeability properties of the lysosomal membrane. Biochim Biophys Acta 1977, 472(3-4):419-449.
49. Meister A., Anderson M.E. Glutathione. Ann Rev Biochem 1983, 52:711-760.
50. Dharap S.S., Wang Y., Chandna P., Khandare J.J., Qiu B., Gunaseelan S., et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci 2005, 102(36):12962-12967.
51. Dharap S.S., Chandna P., Wang Y., Khandare J.J., Qiu B., Stein S., et al. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy. J Pharmacol Exp Ther 2006, 316(3):992-998.
52. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Contr Release 2000, 65(1-2):271-284.
53. Ireson C., Orr S., Jones D.J.L., Verschoyle R., Lim C.-K., Luo J.-L., et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001, 61(3):1058-1064.